Dustarin in the Treatment of Patients with Benign Prostatic Hyperplasia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Today the problem of treatment of patients with benign prostatic hyperplasia (BPH) is the actual one.
BPH is an age-related chronic progressive disease. It is especially relevant for men over the age of 50 years. According to WHO demographic data, the world’s population is becoming older, so the incidence of BPH is going to increase, that leads to a significant decline in quality of life due to dysfunction of the lower urinary tract and the presence of lower urinary tract symptoms (LUTS).
The management of BPH has evolved from surgery to conservative therapy. The use of 5α- reductase inhibitors, which affects the pathogenetic links of the disease, reduces the concentration of dihydrotestosterone and induces the apoptosis of epithelial cells of the prostate, is pathogenetically justified in the treatment of BPH.
The objective: to study the effectiveness of treatment of BPH with dutasteride, which belongs to the group of 5α-reductase inhibitors.
Materials and methods. 58 patients with BPH 52-75 years old were examined. The persons were divided into two groups. The patients in the first group received dutasteride for 6 months, the second group – for 12 months.
All patients were examined ambulatory by the laboratory and instrumental diagnostic methods: an assessment of complaints by the International Prostate Symptom Score (IPSS), an assessment of the quality of life by the QoL scale, digital rectal and ultrasound examinations, bladder ultrasound examination, uroflowmetry, prostate-specific antigen level, general blood and urinary tests, determination of creatinine and urea. Uroflowmetry assessed the rate of urodynamics, identified and determined the degree of urinary disorders .
Results. A positive effect of dutasteride treatment was observed in patients of both groups, but the best results were in the second group. The regression of LUTS, decreased pancreatic volume and residual urine output were in the patients.
Conclusions. The results of the research demonstrated that dutasteride is an effective agent in the treatment of benign prostatic hyperplasia (BPH), which acts on the mechanism of hyperplasia. The drug is well tolerated by patients. The effect of dutasteride treatment is achieved through its continuous and long-term use.
The timely diagnosis of BPH and its treatment will allow to stop the pathological process and return the man to a normal quality of life.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
De Nunzio C, RoehrBorn CG, Andersson K-E, McVary KT. Erectile dysfunction and urinary tract symptoms. Eur Urol Focus. 2017;412:352–63. doi: 10.1016/j.euf.2017.11.004
Kalinina SN, Burlaka OO, Aleksandrov MS. Diagnostika i lecheniye simptomov nizhnikh mochevykh putey i erektilnoy disfunktsii u bol’nykh dobrokachestvennoy giperplaziyey predstatelnoy zhelezy. Urol vedomosti. 2018;1(8):26–33.
Alyayev YUG. Bolezni predstatelnoy zhelezy. Moskva: GEOTAR – Media; 2009. 240 p.
Gorpinchenko II, Gurzhenko YUN, Spiridonenko VV, Kostyuchenko SA, Krasovskiy VM. Issledovaniye effektivnosti preparata Tamsin Forte v lechenii muzhchin s dobrokachestvennoy giperplaziyey predstatelnoy zhelezy. Zdorov’ye muzhchiny. 2017;60(1):79–81.
Simone A, Aouh F, Roumeguere T, Porpiglia F, Tubaro A. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nephrol. 2017;69(2):19–32. doi: 10.23736/S0393-2249.16.02743-0
Kristofer Vu, Anil Kapur Dutasterid dlya lecheniya dobrokachestvennoy giperplazii prostaty. Mneniye eksperta. Farmakoter. 2013;14(10):1339–408.
Sauver JL, Jacobson DJ, Mc.Gree МЕ. Association between prostatitis and development of benign prostatic hyperplasia. J Urol. 2007;177(Suppl.4):497. doi: 10.1016/j.urology.2007.11.155
Kramer G, Mitteregger H, Marberger M. Is benign prostatic hyperplasia (BPH) an Immune Inflammatory Disease? Europ. Urol. 2007;51(5):1202–16. doi: 10.1016/j.eururo.2006.12.011
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW. Biomarkers of systemic inflammation and risk, symptomatic benign prostatic hyperplasia: results of a study on the prevention of prostate cancer. Am J Epidemiol. 2010;171(5):571–82. doi: 10.1093/aje/kwp406
Anderson DzhB, Rorborn KG, Shalken DzhA, Emberton M. Progressirovaniye dobrokachestvennoy giperplazii prostaty: izucheniye dokazatel’stv i opredeleniya riska. Yevr Urol. 2001;39:390–99.
Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urological diseases. Rev Urol. 2010;12(4):157–80. doi: 10.1038/nrurol.2011.112
Espinosa G, Esposito R, Kazzazi A, Djava B. Vitamin D and benign prostatic hyperplasia – a review. Can J Urol. 2013;20(4):6820–25.
Yalçınkaya S, Eren E, Eroglu M. Deficiency of vitamin D and elevated aldosterone in prostate hyperplasia. Adv Clin Exp Med. 2014;23(3):44–6. doi: 10.17219/acem/37143
Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol. 2011;60:1173–180. doi: 10.1016/j.eururo.2011.07.040
Fok G, Phillips S, Koyama T, Byerly S, Concepcion R, Motley SS. The Relationship between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int. 2013;111(1):122–8. doi: 10.1111/j.1464-410X.2012.11287.x
Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–51. doi: 10.1016/j.ajur.2017.06.004
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099–109. doi: 10.1016/j.eururo.2014.12.038
Trukhan DI, Yurenev GL, Makushin DG, Chusova NA. Simptomy nizhnikh mochevykh putey: differentsial’nyy diagnoz na etape okazaniya pervichnoy mediko-sanitarnoy pomoshchi. Spravochnik poliklinicheskogo vracha. 2019;3:23–8.
Iziyev MM, Al-Shukri AS, Tkachuk VN. Sostoyaniye urodinamiki nizhnikh mochevykh putey u bol’nykh dobrokachestvennoy giperplaziyey predstatelnoy zhelezy na fone lecheniya dutasteridom. Urol vedomosti. 2017;7(3):28–33. doi: 10.17816/uroved7328-33
Kamalov AA, Takhirzade AM. Podkhody k medikamentoznomu lecheniyu patsiyentov s vysokim riskom progressirovaniya dobrokachestvennoy giperplazii predstatel’noy zhelezy v zavisimosti ot soputstvuyushchey erektil’noy disfunktsii. Urol. 2018;3:70–7.
